Literature DB >> 21532767

Gardasil® - The New HPV Vaccine: The Right Product, the Right Time? A Commentary.

Joel Lexchin1, Neil Arya, Sonal Singh.   

Abstract

The federal and provincial governments have undertaken a universal immunization program to protect school-aged girls against cervical cancer using the new human papillomavirus vaccine Gardasil®. While the vaccine appears to be effective and safe, there are a number of important unanswered questions regarding it and the effects of the immunization program. Here we briefly review key literature about the vaccine and then use the Erickson criteria, which offer an evidence basis for decision-making regarding national immunization strategies, to evaluate whether the program is congruent with sound public health policy. Our analysis of the national decision to recommend and fund a vaccination program using Gardasil® raises significant questions about the basis for this program.

Entities:  

Year:  2010        PMID: 21532767      PMCID: PMC2875890     

Source DB:  PubMed          Journal:  Healthc Policy        ISSN: 1715-6572


  20 in total

Review 1.  Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.

Authors:  Lisa Rambout; Laura Hopkins; Brian Hutton; Dean Fergusson
Journal:  CMAJ       Date:  2007-08-01       Impact factor: 8.262

2.  An analytical framework for immunization programs in Canada.

Authors:  L J Erickson; P De Wals; L Farand
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

3.  HPV vaccination--more answers, more questions.

Authors:  George F Sawaya; Karen Smith-McCune
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

4.  Mandatory HPV vaccination: public health vs private wealth.

Authors:  Lawrence O Gostin; Catherine D DeAngelis
Journal:  JAMA       Date:  2007-05-02       Impact factor: 56.272

Review 5.  Challenges of implementing human papillomavirus (HPV) vaccination policy.

Authors:  Angela E Raffle
Journal:  BMJ       Date:  2007-08-25

6.  Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty.

Authors:  Nicolas Van de Velde; Marc Brisson; Marie-Claude Boily
Journal:  Am J Epidemiol       Date:  2007-02-01       Impact factor: 4.897

7.  Vaccination against human papillomavirus: a baseline survey of Canadian clinicians' knowledge, attitudes and beliefs.

Authors:  Bernard Duval; Vladimir Gilca; Shelly McNeil; Simon Dobson; Deborah Money; Ian M Gemmill; Chantal Sauvageau; France Lavoie; Manale Ouakki
Journal:  Vaccine       Date:  2007-09-14       Impact factor: 3.641

8.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

9.  The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.

Authors:  Marc Brisson; Nicolas Van de Velde; Philippe De Wals; Marie-Claude Boily
Journal:  Vaccine       Date:  2007-05-22       Impact factor: 3.641

10.  Parental intention to have daughters receive the human papillomavirus vaccine.

Authors:  Gina S Ogilvie; Valencia P Remple; Fawziah Marra; Shelly A McNeil; Monika Naus; Karen L Pielak; Thomas G Ehlen; Simon R Dobson; Deborah M Money; David M Patrick
Journal:  CMAJ       Date:  2007-12-04       Impact factor: 8.262

View more
  1 in total

1.  An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights from the HPV Vaccine in Canada.

Authors:  Ana Komparic; Maxwell J Smith; Alison Thompson
Journal:  Public Health Ethics       Date:  2015-01-29       Impact factor: 1.940

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.